ReP USP - Resultado da busca

Artigo de periodico-carta/editorial
IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. [Carta] (2018)
Campos, Paula de Melo; Machado Neto, João Agostinho ; Lorand-Metze, Irene ; Costa, Fernando Ferreira; Saad, Sara Teresinha Olalla; Traina, Fabiola
Fonte: Hematology, Transfusion and Cell Therapy. Unidades: ICB, FMRP
Assuntos: LEUCEMIA MIELOIDE, CÉLULAS-TRONCO, BIOMARCADORES, MEDULA ÓSSEA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAMPOS, Paula de Melo et al. IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. [Carta]. Hematology, Transfusion and Cell Therapy. Rio de Janeiro: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.bjhh.2017.10.001. Acesso em: 22 out. 2025. , 2018
APA
Campos, P. de M., Machado Neto, J. A., Lorand-Metze, I., Costa, F. F., Saad, S. T. O., & Traina, F. (2018). IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. [Carta]. Hematology, Transfusion and Cell Therapy. Rio de Janeiro: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1016/j.bjhh.2017.10.001
NLM
Campos P de M, Machado Neto JA, Lorand-Metze I, Costa FF, Saad STO, Traina F. IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. [Carta] [Internet]. Hematology, Transfusion and Cell Therapy. 2018 ; 40( 1): 92-95.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/j.bjhh.2017.10.001
Vancouver
Campos P de M, Machado Neto JA, Lorand-Metze I, Costa FF, Saad STO, Traina F. IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. [Carta] [Internet]. Hematology, Transfusion and Cell Therapy. 2018 ; 40( 1): 92-95.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/j.bjhh.2017.10.001
Artigo de periodico
Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (2018)
Magalhães, Silvia Maria Meira; Niero-Melo, Lígia; Chauffaille, Maria de Lourdes Lopes Ferrari; Velloso, Elvira Deolinda Rodrigues Pereira; Lorand-Metze, Irene; Buzzini, Renata; Bernardo, Wanderley Marques
Fonte: Hematology. Unidade: FM
Assuntos: HEMATOLOGIA, ANEMIA, MEDULA ÓSSEA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MAGALHÃES, Silvia Maria Meira et al. Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Hematology, v. 40, n. 3, p. 255-261, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.htct.2018.05.004. Acesso em: 22 out. 2025.
APA
Magalhães, S. M. M., Niero-Melo, L., Chauffaille, M. de L. L. F., Velloso, E. D. R. P., Lorand-Metze, I., Buzzini, R., & Bernardo, W. M. (2018). Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Hematology, 40( 3), 255-261. doi:10.1016/j.htct.2018.05.004
NLM
Magalhães SMM, Niero-Melo L, Chauffaille M de LLF, Velloso EDRP, Lorand-Metze I, Buzzini R, Bernardo WM. Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular [Internet]. Hematology. 2018 ; 40( 3): 255-261.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/j.htct.2018.05.004
Vancouver
Magalhães SMM, Niero-Melo L, Chauffaille M de LLF, Velloso EDRP, Lorand-Metze I, Buzzini R, Bernardo WM. Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular [Internet]. Hematology. 2018 ; 40( 3): 255-261.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/j.htct.2018.05.004
Artigo de periodico
SIVA, a target of p53, is downregulated in myelodysplastic syndromes (2017)
Machado Neto, João Agostinho ; Campos, Paula de Melo; Favaro, Patricia; Lazarini, Mariana; Scopim-Ribeiro, Renata; Lorand-Metze, Irene; Costa, Fernando Ferreira; Saad, Sara Terezinha Olalla; Traina, Fabiola
Fonte: Applied Cancer Research. Unidade: FMRP
Assuntos: LEUCEMIA, MEDULA ÓSSEA, EXPRESSÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO NETO, João Agostinho et al. SIVA, a target of p53, is downregulated in myelodysplastic syndromes. Applied Cancer Research, v. 37, p. 7 , 2017Tradução . . Disponível em: https://doi.org/10.1186/s41241-017-0033-9. Acesso em: 22 out. 2025.
APA
Machado Neto, J. A., Campos, P. de M., Favaro, P., Lazarini, M., Scopim-Ribeiro, R., Lorand-Metze, I., et al. (2017). SIVA, a target of p53, is downregulated in myelodysplastic syndromes. Applied Cancer Research, 37, 7 . doi:10.1186/s41241-017-0033-9
NLM
Machado Neto JA, Campos P de M, Favaro P, Lazarini M, Scopim-Ribeiro R, Lorand-Metze I, Costa FF, Saad STO, Traina F. SIVA, a target of p53, is downregulated in myelodysplastic syndromes [Internet]. Applied Cancer Research. 2017 ; 37 7 .[citado 2025 out. 22 ] Available from: https://doi.org/10.1186/s41241-017-0033-9
Vancouver
Machado Neto JA, Campos P de M, Favaro P, Lazarini M, Scopim-Ribeiro R, Lorand-Metze I, Costa FF, Saad STO, Traina F. SIVA, a target of p53, is downregulated in myelodysplastic syndromes [Internet]. Applied Cancer Research. 2017 ; 37 7 .[citado 2025 out. 22 ] Available from: https://doi.org/10.1186/s41241-017-0033-9
Artigo de periodico
IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms (2016)
Campos, Paula de Melo; Machado Neto, João Agostinho ; Eide, Christopher A.; Savage, Samantha L.; Scopim-Ribeiro, Renata; Duarte, Adriana da Silva Souza; Favaro, Patrícia; Lorand-Metze, Irene; Costa, Fernando F.; Tognon, Cristina E.; Druker, Brian J.; Saad, Sara T. Olalla; Traina, Fabiola
Fonte: Oncotarget. Unidade: FMRP
Assuntos: REAÇÃO EM CADEIA POR POLIMERASE, APOPTOSE, MUTAÇÃO GENÉTICA, LEUCEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAMPOS, Paula de Melo et al. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget, v. 7, n. 6, p. 6948-6959, 2016Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.6851. Acesso em: 22 out. 2025.
APA
Campos, P. de M., Machado Neto, J. A., Eide, C. A., Savage, S. L., Scopim-Ribeiro, R., Duarte, A. da S. S., et al. (2016). IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget, 7( 6), 6948-6959. doi:10.18632/oncotarget.6851
NLM
Campos P de M, Machado Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, Duarte A da SS, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Saad STO, Traina F. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms [Internet]. Oncotarget. 2016 ; 7( 6): 6948-6959.[citado 2025 out. 22 ] Available from: https://doi.org/10.18632/oncotarget.6851
Vancouver
Campos P de M, Machado Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, Duarte A da SS, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Saad STO, Traina F. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms [Internet]. Oncotarget. 2016 ; 7( 6): 6948-6959.[citado 2025 out. 22 ] Available from: https://doi.org/10.18632/oncotarget.6851
Artigo de periodico
Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms (2016)
Scopim-Ribeiro, Renata; Machado Neto, João Agostinho ; Campos, Paula de Melo; Niemann, Fernanda Soares; Lorand-Metze, Irene; Costa, Fernando Ferreira; Saad, Sara Teresinha Olalla; Traina, Fabiola
Fonte: Diagnostic Pathology. Unidade: FMRP
Assuntos: LEUCEMIA MIELOIDE AGUDA, BIOMARCADORES, PROTEÍNAS PROTO-ONCOGÊNICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCOPIM-RIBEIRO, Renata et al. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. Diagnostic Pathology, v. 11, n. 1, 2016Tradução . . Disponível em: https://doi.org/10.1186/s13000-016-0476-4. Acesso em: 22 out. 2025.
APA
Scopim-Ribeiro, R., Machado Neto, J. A., Campos, P. de M., Niemann, F. S., Lorand-Metze, I., Costa, F. F., et al. (2016). Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. Diagnostic Pathology, 11( 1). doi:10.1186/s13000-016-0476-4
NLM
Scopim-Ribeiro R, Machado Neto JA, Campos P de M, Niemann FS, Lorand-Metze I, Costa FF, Saad STO, Traina F. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms [Internet]. Diagnostic Pathology. 2016 ; 11( 1):[citado 2025 out. 22 ] Available from: https://doi.org/10.1186/s13000-016-0476-4
Vancouver
Scopim-Ribeiro R, Machado Neto JA, Campos P de M, Niemann FS, Lorand-Metze I, Costa FF, Saad STO, Traina F. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms [Internet]. Diagnostic Pathology. 2016 ; 11( 1):[citado 2025 out. 22 ] Available from: https://doi.org/10.1186/s13000-016-0476-4
Artigo de periodico
Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes (2015)
Scopim-Ribeiro, Renata; Machado Neto, João Agostinho ; Campos, Paula de Melo; Silva, Cleide Aparecida Moreira; Favaro, Patricia; Lorand-Metze, Irene; Costa, Fernando Ferreira; Saad, Sara Teresinha Olalla; Traina, Fabiola
Fonte: European Journal of Haematology. Unidade: FMRP
Assuntos: LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS DE TECIDO NERVOSO, MUTAÇÃO GENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCOPIM-RIBEIRO, Renata et al. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes. European Journal of Haematology, v. 94, n. 5, p. 413-418, 2015Tradução . . Disponível em: https://doi.org/10.1111/ejh.12445. Acesso em: 22 out. 2025.
APA
Scopim-Ribeiro, R., Machado Neto, J. A., Campos, P. de M., Silva, C. A. M., Favaro, P., Lorand-Metze, I., et al. (2015). Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes. European Journal of Haematology, 94( 5), 413-418. doi:10.1111/ejh.12445
NLM
Scopim-Ribeiro R, Machado Neto JA, Campos P de M, Silva CAM, Favaro P, Lorand-Metze I, Costa FF, Saad STO, Traina F. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes [Internet]. European Journal of Haematology. 2015 ; 94( 5): 413-418.[citado 2025 out. 22 ] Available from: https://doi.org/10.1111/ejh.12445
Vancouver
Scopim-Ribeiro R, Machado Neto JA, Campos P de M, Silva CAM, Favaro P, Lorand-Metze I, Costa FF, Saad STO, Traina F. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes [Internet]. European Journal of Haematology. 2015 ; 94( 5): 413-418.[citado 2025 out. 22 ] Available from: https://doi.org/10.1111/ejh.12445
Artigo de periodico
Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors (2015)
Reis-Alves, Suiellen C.; Traina, Fabíola; Metze, Konradin; Lorand-Metze, Irene
Fonte: Diabetology & Metabolic Syndrome. Unidade: FMRP
Assuntos: DOENÇAS HEMATOLÓGICAS, IMUNOFENOTIPAGEM, CITOMETRIA DE FLUXO, MEDULA ÓSSEA, LEUCEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
REIS-ALVES, Suiellen C. et al. Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors. Diabetology & Metabolic Syndrome, v. 10, 2015Tradução . . Disponível em: https://doi.org/10.1186/s13000-015-0259-3. Acesso em: 22 out. 2025.
APA
Reis-Alves, S. C., Traina, F., Metze, K., & Lorand-Metze, I. (2015). Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors. Diabetology & Metabolic Syndrome, 10. doi:10.1186/s13000-015-0259-3
NLM
Reis-Alves SC, Traina F, Metze K, Lorand-Metze I. Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors [Internet]. Diabetology & Metabolic Syndrome. 2015 ; 10[citado 2025 out. 22 ] Available from: https://doi.org/10.1186/s13000-015-0259-3
Vancouver
Reis-Alves SC, Traina F, Metze K, Lorand-Metze I. Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors [Internet]. Diabetology & Metabolic Syndrome. 2015 ; 10[citado 2025 out. 22 ] Available from: https://doi.org/10.1186/s13000-015-0259-3
Artigo de periodico-carta/editorial
Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. [Carta] (2015)
Machado Neto, João Agostinho ; Campos, Paula de Melo; Albuquerque, Dulcinéia Martins de; Costa, Fernando Ferreira; Lorand-Metze, Irene; Saad, Sara Terezinha Olalla; Traina, Fabiola
Fonte: Revista Brasileira de Hematologia e Hemoterapia. Unidade: FMRP
Assuntos: NEOPLASIAS, MUTAÇÃO GENÉTICA, EXPRESSÃO GÊNICA, DIAGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO NETO, João Agostinho et al. Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. [Carta]. Revista Brasileira de Hematologia e Hemoterapia. São Paulo: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.bjhh.2015.03.012. Acesso em: 22 out. 2025. , 2015
APA
Machado Neto, J. A., Campos, P. de M., Albuquerque, D. M. de, Costa, F. F., Lorand-Metze, I., Saad, S. T. O., & Traina, F. (2015). Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. [Carta]. Revista Brasileira de Hematologia e Hemoterapia. São Paulo: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.bjhh.2015.03.012
NLM
Machado Neto JA, Campos P de M, Albuquerque DM de, Costa FF, Lorand-Metze I, Saad STO, Traina F. Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. [Carta] [Internet]. Revista Brasileira de Hematologia e Hemoterapia. 2015 ; 37( 3): 211-214.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/j.bjhh.2015.03.012
Vancouver
Machado Neto JA, Campos P de M, Albuquerque DM de, Costa FF, Lorand-Metze I, Saad STO, Traina F. Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. [Carta] [Internet]. Revista Brasileira de Hematologia e Hemoterapia. 2015 ; 37( 3): 211-214.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/j.bjhh.2015.03.012
Artigo de periodico
Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412 (2014)
Campos, Paula de Melo; Machado Neto, João Agostinho ; Scopim-Ribeiro, Renata; Visconte, Valeria; Tabarroki, Ali; Duarte, Adriana S. S; Barra, Flávia F. C; Vassalo, José; Rogers, Heesun J; Lorand-Metze, Irene; Tiu, Ramon V; Costa, Fernando F; Saad, Sara T. Olalla; Traina, Fabiola
Fonte: Leukemia Research. Unidade: FMRP
Assuntos: APOPTOSE (EFEITOS DE DROGAS), PROTEÍNAS PROTO-ONCOGÊNICAS, PROTEÍNAS QUINASES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAMPOS, Paula de Melo et al. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leukemia Research, v. 38, n. 10, p. 1245-1251, 2014Tradução . . Disponível em: https://doi.org/10.1016/j.leukres.2014.07.010. Acesso em: 22 out. 2025.
APA
Campos, P. de M., Machado Neto, J. A., Scopim-Ribeiro, R., Visconte, V., Tabarroki, A., Duarte, A. S. S., et al. (2014). Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leukemia Research, 38( 10), 1245-1251. doi:10.1016/j.leukres.2014.07.010
NLM
Campos P de M, Machado Neto JA, Scopim-Ribeiro R, Visconte V, Tabarroki A, Duarte ASS, Barra FFC, Vassalo J, Rogers HJ, Lorand-Metze I, Tiu RV, Costa FF, Saad STO, Traina F. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412 [Internet]. Leukemia Research. 2014 ; 38( 10): 1245-1251.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/j.leukres.2014.07.010
Vancouver
Campos P de M, Machado Neto JA, Scopim-Ribeiro R, Visconte V, Tabarroki A, Duarte ASS, Barra FFC, Vassalo J, Rogers HJ, Lorand-Metze I, Tiu RV, Costa FF, Saad STO, Traina F. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412 [Internet]. Leukemia Research. 2014 ; 38( 10): 1245-1251.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/j.leukres.2014.07.010
Artigo de periodico
Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else (2014)
Campos, Paula de Melo; Traina, Fabiola; Lorand-Metze, Irene; Saad, Sara Teresinha Olalla
Fonte: Revista Brasileira de Hematologia e Hemoterapia. Unidade: FMRP
Assuntos: LEUCEMIA MIELOIDE, NEOPLASIAS, DOENÇAS SANGUÍNEAS E LINFÁTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAMPOS, Paula de Melo et al. Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else. Revista Brasileira de Hematologia e Hemoterapia, v. 36, n. 6, p. 442-444, 2014Tradução . . Disponível em: https://doi.org/10.1016/j.bjhh.2014.07.005. Acesso em: 22 out. 2025.
APA
Campos, P. de M., Traina, F., Lorand-Metze, I., & Saad, S. T. O. (2014). Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else. Revista Brasileira de Hematologia e Hemoterapia, 36( 6), 442-444. doi:10.1016/j.bjhh.2014.07.005
NLM
Campos P de M, Traina F, Lorand-Metze I, Saad STO. Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else [Internet]. Revista Brasileira de Hematologia e Hemoterapia. 2014 ; 36( 6): 442-444.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/j.bjhh.2014.07.005
Vancouver
Campos P de M, Traina F, Lorand-Metze I, Saad STO. Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else [Internet]. Revista Brasileira de Hematologia e Hemoterapia. 2014 ; 36( 6): 442-444.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/j.bjhh.2014.07.005
Artigo de periodico
Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells (2014)
Machado Neto, João Agostinho ; Campos, Paula de Melo; Favaro, Patricia; Lazarini, Mariana; Lorand-Metze, Irene; Costa, Fernando Ferreira; Saad, Sara Teresinha Olalla; Traina, Fabiola
Fonte: Leukemia Research. Unidade: FMRP
Assuntos: PROLIFERAÇÃO CELULAR, LEUCEMIA MIELOIDE AGUDA, CÉLULAS CULTIVADAS DE TUMOR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO NETO, João Agostinho et al. Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. Leukemia Research, v. 38, n. 2, p. 251-257, 2014Tradução . . Disponível em: https://doi.org/10.1016/j.leukres.2013.11.013. Acesso em: 22 out. 2025.
APA
Machado Neto, J. A., Campos, P. de M., Favaro, P., Lazarini, M., Lorand-Metze, I., Costa, F. F., et al. (2014). Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. Leukemia Research, 38( 2), 251-257. doi:10.1016/j.leukres.2013.11.013
NLM
Machado Neto JA, Campos P de M, Favaro P, Lazarini M, Lorand-Metze I, Costa FF, Saad STO, Traina F. Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells [Internet]. Leukemia Research. 2014 ; 38( 2): 251-257.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/j.leukres.2013.11.013
Vancouver
Machado Neto JA, Campos P de M, Favaro P, Lazarini M, Lorand-Metze I, Costa FF, Saad STO, Traina F. Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells [Internet]. Leukemia Research. 2014 ; 38( 2): 251-257.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/j.leukres.2013.11.013
Trabalho de evento-resumo
FMNL1 is downregulated in myelodysplastic syndromes and is involved in megakaryocytic differentiation (2013)
Lopes, Matheus Rodrigues; Machado Neto, João Agostinho ; Traina, Fabíola; Pereira, João Kleber Novais; Lorand-Metze, Irene; Costa, Fernando Ferreira; Saad, Sara Teresinha Ollala; Favaro, Patricia
Fonte: Abstracts, Program and Personal Scheduler. Nome do evento: Annual Meeting and Exposition of American Society of Hematology (ASH). Unidade: FMRP
Assuntos: DOENÇAS HEMATOLÓGICAS, HEMATOPOESE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LOPES, Matheus Rodrigues et al. FMNL1 is downregulated in myelodysplastic syndromes and is involved in megakaryocytic differentiation. 2013, Anais.. New Orleans: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, 2013. Disponível em: https://ash.confex.com/ash/2013/webprogram/Paper60188.html. Acesso em: 22 out. 2025.
APA
Lopes, M. R., Machado Neto, J. A., Traina, F., Pereira, J. K. N., Lorand-Metze, I., Costa, F. F., et al. (2013). FMNL1 is downregulated in myelodysplastic syndromes and is involved in megakaryocytic differentiation. In Abstracts, Program and Personal Scheduler. New Orleans: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Recuperado de https://ash.confex.com/ash/2013/webprogram/Paper60188.html
NLM
Lopes MR, Machado Neto JA, Traina F, Pereira JKN, Lorand-Metze I, Costa FF, Saad STO, Favaro P. FMNL1 is downregulated in myelodysplastic syndromes and is involved in megakaryocytic differentiation [Internet]. Abstracts, Program and Personal Scheduler. 2013 ;[citado 2025 out. 22 ] Available from: https://ash.confex.com/ash/2013/webprogram/Paper60188.html
Vancouver
Lopes MR, Machado Neto JA, Traina F, Pereira JKN, Lorand-Metze I, Costa FF, Saad STO, Favaro P. FMNL1 is downregulated in myelodysplastic syndromes and is involved in megakaryocytic differentiation [Internet]. Abstracts, Program and Personal Scheduler. 2013 ;[citado 2025 out. 22 ] Available from: https://ash.confex.com/ash/2013/webprogram/Paper60188.html
Trabalho de evento-resumo
Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells (2013)
Machado Neto, João Agostinho ; Campos, Paula de Melo; Favaro, Patricia; Lazarini, Mariana; Lorand-Metze, Irene; Costa, Fernando Ferreira; Saad, Sara Teresinha Ollala; Traina, Fabíola
Fonte: Abstracts, Program and Personal Scheduler. Nome do evento: Annual Meeting and Exposition of American Society of Hematology (ASH). Unidade: FMRP
Assuntos: LEUCEMIA MIELOIDE AGUDA, HEMATOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO NETO, João Agostinho et al. Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. 2013, Anais.. New Orleans: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, 2013. Disponível em: https://ash.confex.com/ash/2013/webprogram/Paper57514.html. Acesso em: 22 out. 2025.
APA
Machado Neto, J. A., Campos, P. de M., Favaro, P., Lazarini, M., Lorand-Metze, I., Costa, F. F., et al. (2013). Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. In Abstracts, Program and Personal Scheduler. New Orleans: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Recuperado de https://ash.confex.com/ash/2013/webprogram/Paper57514.html
NLM
Machado Neto JA, Campos P de M, Favaro P, Lazarini M, Lorand-Metze I, Costa FF, Saad STO, Traina F. Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells [Internet]. Abstracts, Program and Personal Scheduler. 2013 ;[citado 2025 out. 22 ] Available from: https://ash.confex.com/ash/2013/webprogram/Paper57514.html
Vancouver
Machado Neto JA, Campos P de M, Favaro P, Lazarini M, Lorand-Metze I, Costa FF, Saad STO, Traina F. Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells [Internet]. Abstracts, Program and Personal Scheduler. 2013 ;[citado 2025 out. 22 ] Available from: https://ash.confex.com/ash/2013/webprogram/Paper57514.html
Trabalho de evento-resumo
IRS2 associates with JAK2 and may be involved in cell proliferation pathways in chronic myeloproliferative neoplasms (2013)
Campos, Paula de Melo; Machado Neto, João Agostinho ; Duarte, Adriana Silva Santos; Mendonça, Rafaela; Lorand-Metze, Irene; Costa, Fernando Ferreira; Saad, Sara Teresinha Ollala; Traina, Fabíola
Fonte: Abstracts, Program and Personal Scheduler. Nome do evento: Annual Meeting and Exposition of American Society of Hematology (ASH). Unidade: FMRP
Assuntos: MUTAÇÃO GENÉTICA, NEOPLASIAS, DOENÇAS HEMATOLÓGICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAMPOS, Paula de Melo et al. IRS2 associates with JAK2 and may be involved in cell proliferation pathways in chronic myeloproliferative neoplasms. 2013, Anais.. New Orleans: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, 2013. Disponível em: https://ash.confex.com/ash/2013/webprogram/Paper62742.html. Acesso em: 22 out. 2025.
APA
Campos, P. de M., Machado Neto, J. A., Duarte, A. S. S., Mendonça, R., Lorand-Metze, I., Costa, F. F., et al. (2013). IRS2 associates with JAK2 and may be involved in cell proliferation pathways in chronic myeloproliferative neoplasms. In Abstracts, Program and Personal Scheduler. New Orleans: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Recuperado de https://ash.confex.com/ash/2013/webprogram/Paper62742.html
NLM
Campos P de M, Machado Neto JA, Duarte ASS, Mendonça R, Lorand-Metze I, Costa FF, Saad STO, Traina F. IRS2 associates with JAK2 and may be involved in cell proliferation pathways in chronic myeloproliferative neoplasms [Internet]. Abstracts, Program and Personal Scheduler. 2013 ;[citado 2025 out. 22 ] Available from: https://ash.confex.com/ash/2013/webprogram/Paper62742.html
Vancouver
Campos P de M, Machado Neto JA, Duarte ASS, Mendonça R, Lorand-Metze I, Costa FF, Saad STO, Traina F. IRS2 associates with JAK2 and may be involved in cell proliferation pathways in chronic myeloproliferative neoplasms [Internet]. Abstracts, Program and Personal Scheduler. 2013 ;[citado 2025 out. 22 ] Available from: https://ash.confex.com/ash/2013/webprogram/Paper62742.html
Artigo de periodico
Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma (2012)
Maiolino, Angelo; Hungria, Vania T. M.; Garnica, Marcia; Duarte, Gislaine Oliveira; Oliveira, Luciana Corrêa Oliveira de; Mercante, Daniel R.; Miranda, Eliana C.; Quero, Adriana A.; Peres, Ana L. M.; Barros, José C.; Tanaka, Paola; Magalhães, Roberto P.; Rego, Eduardo Magalhães; Lorand-Metze, Irene; Lima, Carmen S. P.; Renault, Ilana Z.; Braggio, Esteban; Chiattone, Carlos; Nucci, Márcio; Souza, Carmino A. de
Fonte: American Journal of Hematology. Unidade: FMRP
Assuntos: ANTINEOPLÁSICOS, TERAPIA COMBINADA, MIELOMA MÚLTIPLO, MODELOS DE RISCOS PROPORCIONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MAIOLINO, Angelo et al. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. American Journal of Hematology, v. 87, n. 10, p. 948-952, 2012Tradução . . Disponível em: https://doi.org/10.1002/ajh.23274. Acesso em: 22 out. 2025.
APA
Maiolino, A., Hungria, V. T. M., Garnica, M., Duarte, G. O., Oliveira, L. C. O. de, Mercante, D. R., et al. (2012). Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. American Journal of Hematology, 87( 10), 948-952. doi:10.1002/ajh.23274
NLM
Maiolino A, Hungria VTM, Garnica M, Duarte GO, Oliveira LCO de, Mercante DR, Miranda EC, Quero AA, Peres ALM, Barros JC, Tanaka P, Magalhães RP, Rego EM, Lorand-Metze I, Lima CSP, Renault IZ, Braggio E, Chiattone C, Nucci M, Souza CA de. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma [Internet]. American Journal of Hematology. 2012 ; 87( 10): 948-952.[citado 2025 out. 22 ] Available from: https://doi.org/10.1002/ajh.23274
Vancouver
Maiolino A, Hungria VTM, Garnica M, Duarte GO, Oliveira LCO de, Mercante DR, Miranda EC, Quero AA, Peres ALM, Barros JC, Tanaka P, Magalhães RP, Rego EM, Lorand-Metze I, Lima CSP, Renault IZ, Braggio E, Chiattone C, Nucci M, Souza CA de. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma [Internet]. American Journal of Hematology. 2012 ; 87( 10): 948-952.[citado 2025 out. 22 ] Available from: https://doi.org/10.1002/ajh.23274
Artigo de periodico
The brazilian pediatric myelodysplastic cooperative group strategies: are they relevant to improve educational approach and correct diagnosis ? (2002)
Lopes, Luiz Fernando; Lorand-Metze, Irene; Niero-Melo, Ligia; Tone, Luiz Gonzaga; Velloso, Elvira; Campanaro, Célia; Latorre, Maria do Rosário Dias de Oliveira
Fonte: Leukemia Research. Unidades: FMRP, FSP
Assuntos: ONCOLOGIA, PEDIATRIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LOPES, Luiz Fernando et al. The brazilian pediatric myelodysplastic cooperative group strategies: are they relevant to improve educational approach and correct diagnosis ?. Leukemia Research, v. 26, p. 637-642, 2002Tradução . . Disponível em: https://doi.org/10.1016/s0145-2126(01)00187-4. Acesso em: 22 out. 2025.
APA
Lopes, L. F., Lorand-Metze, I., Niero-Melo, L., Tone, L. G., Velloso, E., Campanaro, C., & Latorre, M. do R. D. de O. (2002). The brazilian pediatric myelodysplastic cooperative group strategies: are they relevant to improve educational approach and correct diagnosis ? Leukemia Research, 26, 637-642. doi:10.1016/s0145-2126(01)00187-4
NLM
Lopes LF, Lorand-Metze I, Niero-Melo L, Tone LG, Velloso E, Campanaro C, Latorre M do RD de O. The brazilian pediatric myelodysplastic cooperative group strategies: are they relevant to improve educational approach and correct diagnosis ? [Internet]. Leukemia Research. 2002 ; 26 637-642.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/s0145-2126(01)00187-4
Vancouver
Lopes LF, Lorand-Metze I, Niero-Melo L, Tone LG, Velloso E, Campanaro C, Latorre M do RD de O. The brazilian pediatric myelodysplastic cooperative group strategies: are they relevant to improve educational approach and correct diagnosis ? [Internet]. Leukemia Research. 2002 ; 26 637-642.[citado 2025 out. 22 ] Available from: https://doi.org/10.1016/s0145-2126(01)00187-4
Trabalho de evento-resumo periodico
Pediatric MDS in Brazil: the brazilian working group on MDS in childhood, first results and its educational impact (2001)
Lopes, Luiz Fernando; Melo, Ligia Niero; Lorand-Metze, Irene; Tone, Luiz Gonzaga; Velloso, Elvira; Lattore, Maria do Rosário
Fonte: Medical and Pediatric Oncology. Nome do evento: Meeting of the International Society of Paediatric Oncology. Unidade: FMRP
Assuntos: ONCOLOGIA, PEDIATRIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LOPES, Luiz Fernando et al. Pediatric MDS in Brazil: the brazilian working group on MDS in childhood, first results and its educational impact. Medical and Pediatric Oncology. New York: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 22 out. 2025. , 2001
APA
Lopes, L. F., Melo, L. N., Lorand-Metze, I., Tone, L. G., Velloso, E., & Lattore, M. do R. (2001). Pediatric MDS in Brazil: the brazilian working group on MDS in childhood, first results and its educational impact. Medical and Pediatric Oncology. New York: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.
NLM
Lopes LF, Melo LN, Lorand-Metze I, Tone LG, Velloso E, Lattore M do R. Pediatric MDS in Brazil: the brazilian working group on MDS in childhood, first results and its educational impact. Medical and Pediatric Oncology. 2001 ; 37( 3): 261 res. P211.[citado 2025 out. 22 ]
Vancouver
Lopes LF, Melo LN, Lorand-Metze I, Tone LG, Velloso E, Lattore M do R. Pediatric MDS in Brazil: the brazilian working group on MDS in childhood, first results and its educational impact. Medical and Pediatric Oncology. 2001 ; 37( 3): 261 res. P211.[citado 2025 out. 22 ]

Unidades USP

ReP

Filtros

Departamento

Autores

Autores USP

Ano de publicação

Assuntos

Título da fonte

Agência de fomento

Indexado em

Afiliação dos autores externos não normalizada